Neurocrine Biosciences (NBIX) Cash from Financing Activities (2010 - 2026)
Neurocrine Biosciences' Cash from Financing Activities was $63.4 million in Q2 2026, compared with -$3.3 million a year earlier.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Cash from Financing Activities (2010 - 2026) Analysis & Trends
On a trailing twelve-month basis, Neurocrine Biosciences' Cash from Financing Activities was $60.2 million through Jun 30, 2026; for FY2025, it came in at -$38.3 million.
- In earlier years, Cash from Financing Activities was -$486.7 million in FY2024, $65.3 million in FY2023, -$234.3 million in FY2022 and $27.4 million in FY2021.
- The Q2 2026 figure marks the highest quarterly Cash from Financing Activities since Q1 2024.
- The best year-over-year quarter for Cash from Financing Activities over five years was Q1 2024 (growth of 752.4%); the worst was Q1 2022 (a decline of 59.6%).
- Per Business Quant data, NBIX's Cash from Financing Activities in the three quarters before Q2 2026 was -$86.1 million (Q1 2026), $37.3 million (Q4 2025) and $45.6 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | -8.78 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | -5.05 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 1.76 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | -2.02 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | -47.00 Mn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | -1.48 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 2.34 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | -3.66 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | -426.70 Mn |
| 10 | Neurocrine Biosciences | 14.41 Bn | 10.11 Bn | 935.80 Mn | 63.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 63.40 Mn |
| Mar 31, 2026 | -86.10 Mn |
| Dec 31, 2025 | 37.30 Mn |
| Sep 30, 2025 | 45.60 Mn |
| Jun 30, 2025 | -3.30 Mn |
| Mar 31, 2025 | -117.90 Mn |
| Dec 31, 2024 | -290.00 Mn |
| Sep 30, 2024 | 26.40 Mn |
| Jun 30, 2024 | -293.00 Mn |
| Mar 31, 2024 | 69.90 Mn |
| Dec 31, 2023 | 35.40 Mn |
| Sep 30, 2023 | 18.80 Mn |
| Jun 30, 2023 | 2.90 Mn |
| Mar 31, 2023 | 8.20 Mn |
| Dec 31, 2022 | 24.60 Mn |
| Sep 30, 2022 | 11.40 Mn |
| Jun 30, 2022 | -276.40 Mn |
| Mar 31, 2022 | 6.10 Mn |
| Dec 31, 2021 | 1.80 Mn |
| Sep 30, 2021 | 7.50 Mn |
API Access
Neurocrine Biosciences Cash from Financing Activities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-from-financing-activities", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();